CoChat

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues

Sherratt, Samuel C. R., Libby, Peter, Budoff, Matthew J., Bhatt, Deepak L., Mason, R. Preston · 2023 · Current Atherosclerosis Reports
Cited by 129

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Purpose of Review: The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce residual cardiovascular (CV) risk among statin-treated subjects. The outcome trials have yielded highly inconsistent results, perhaps attributable to variations in dosage, formulation, and composition. In particular, CV trials using icosapent ethyl (IPE), a highly purified ethyl ester of EPA, reproducibly reduced CV events and progression of atherosclerosis compared with mixed EPA/DHA treatments. This review summarizes the mechanistic evidence for differences among n3-FAs on the development and manifestations of atherothrombotic disease. Recent Findings: Large randomized clinical trials with n3-FAs have produced discordant outcomes despite similar patient profiles, doses, and triglyceride (TG)-lowering effects. A large, randomized trial with IPE, a prescription EPA only formulation, showed robust reduction in CV events in statin treated patients in a manner proportional to achieved blood EPA concentrations. Multiple trials using mixed EPA/DHA formulations have not shown such benefits, despite similar TG lowering. These inconsistencies have inspired investigations into mechanistic differences among n3-FAs, as EPA and DHA have distinct membrane interactions, metabolic products, effects on cholesterol efflux, antioxidant properties, and tissue distribution. EPA maintains normal membrane cholesterol distribution, enhances endothelial function, and in combination with statins improves features implicated in plaque stability and reduces lipid content of plaques. Summary: Insights into reductions in residual CV risk have emerged from clinical trials using different formulations of n3-FAs. Among high-risk patients on contemporary care, mixed n3-FA formulations showed no reduction in CV events. The distinct benefits of IPE in multiple trials may arise from pleiotropic actions that correlate with on-treatment EPA levels beyond TG-lowering. These effects include altered platelet function, inflammation, cholesterol distribution, and endothelial dysfunction. Elucidating such mechanisms of vascular protection for EPA may lead to new interventions for atherosclerosis, a disease that continues to expand worldwide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11883-022-01075-x

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Research works printed but not linked: 90

  1. Burgess S, et al. Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions. PLoS ONE. 2014;9:e108891. · DOI · Paper page
  2. Hansen SEJ, et al. Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. Clin Chem. 2019;65:321–32. · DOI · Paper page
  3. Mason RP, et al. Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction. Metabolism - Clinical and Experimental. 2022;130. · DOI
  4. Mason RP, Eckel RH. Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction. Am J Med. 2021;134:1085–90. · DOI
  5. Sherratt SCR, et al. A Biological Rationale for the Disparate Effects of Omega-3 Fatty Acids on Cardiovascular Disease Outcomes. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2022:102450. · DOI · Paper page
  6. Vallejo-Vaz AJ, et al. Triglycerides and residual risk. Curr Opin Endocrinol Diabetes Obes. 2020;27:95–103. · DOI
  7. Onat UI, et al. Intercepting the Lipid-Induced Integrated Stress Response Reduces Atherosclerosis. J Am Coll Cardiol. 2019;73:1149–69. · DOI
  8. Martínez GJ, et al. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–71. · DOI · Paper page
  9. Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16:149. · DOI · Paper page
  10. Quesada-López T, et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat Commun. 2016;7:13479. · DOI · Paper page
  11. Gotoh C, et al. The regulation of adipogenesis through GPR120. Biochem Biophys Res Commun. 2007;354:591–7. · DOI · Paper page
  12. Dubois V, et al. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Investig. 2017;127:1202–14. · DOI · Paper page
  13. Grevengoed TJ, et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. The Journal of Clinical Investigation. 2021;131. · DOI
  14. Peterson BE, et al. Reduction in Revascularization With Icosapent Ethyl. Circulation. 2021;143:33–44. · DOI · Paper page
  15. Peterson BE, et al. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention- insights from REDUCE-IT PCI. J Am Heart Assoc. 2022;11:e022937. · DOI · Paper page
  16. Gaba P, et al. Prevention of ischemic events and mortality with icosapent ethyl in patients with prior myocardial infarction. Journal of the American College of Cardiology. 2022;In Press. · DOI · Paper page
  17. Verma S, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021;144:1845–55. · DOI
  18. Singh N, et al. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220–2. · DOI
  19. • Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369:1090–8. (This is the original data manuscript of the JELIS trial, which showed significant cardiovascular event reduction in hypercholesterolemic patients with EPA ethyl ester added to statin therapy.) · DOI · Paper page
  20. Pisaniello AD, et al. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. European Medical Journal. 2020;5:29–36.
  21. Watanabe T, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537–44. · DOI · Paper page
  22. • Budoff MJ, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925–32. (The EVAPORATE trial provides mechanistic insight into the benefits of icospaent ethyl on atherosclerotic cardiovascular events, where plaque volume not only attenuated by also regressed.) · DOI · Paper page
  23. Williams MC, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction. Circulation. 2020;141:1452–62. · DOI · Paper page
  24. • Sato T, et al. Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques. Arterioscler Thromb Vasc Biol. 2019;39:1802–16. (This study showed that EPA preferntially incorporates into atherosclerotic plaques compared to DHA and other novel mechanisms of atheroprotection with EPA.) · DOI
  25. Cawood AL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252–9. · DOI · Paper page
  26. • Aung T, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiology. 2018;3:225–33. (This meta analysis, performed in 2018 prior to the REDUCE-IT and STRENGTH trials, showed no significant benefit with omega-3 fatty acid supplementation on cardiovascular disease events.) · DOI · Paper page
  27. Kwak SM, et al. Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind. Placebo-Controlled Trials Archives of Internal Medicine. 2012;172:686–94. · DOI
  28. Rizos EC, et al. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis. JAMA. 2012;308:1024–33. · DOI · Paper page
  29. Kapoor K, et al. Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. J Clin Lipidol. 2021;15:545–55. · DOI
  30. Myhre P, et al. Changes in EPA and DHA during supplementation with omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial. European Heart Journal. 2021;42. · DOI
  31. Gopaul VS, et al. Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. Eur J Pharm Sci. 2021;161:105776. · DOI
  32. Bhatt DL, et al. A Revolution in Omega-3 Fatty Acid Research∗. J Am Coll Cardiol. 2020;76:2098–101. · DOI
  33. Burdge GC, et al. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]α-linolenic acid to longer-chain fatty acids and partitioning towards β-oxidation in older men. Br J Nutr. 2003;90:311–21. · DOI · Paper page
  34. Giltay EJ, et al. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am J Clin Nutr. 2004;80:1167–74. · DOI · Paper page
  35. Otto SJ, et al. Changes in the maternal essential fatty acid profile during early pregnancy and the relation of the profile to diet. Am J Clin Nutr. 2001;73:302–7. · DOI
  36. Bergé J-P, Barnathan G. Fatty Acids from Lipids of Marine Organisms: Molecular Biodiversity, Rolesas Biomarkers, Biologically Active Compounds, and Economical Aspects. In: Ulber R, Le Gal Y, editors. Marine Biotechnology I Berlin. Heidelberg: Springer, Berlin Heidelberg; 2005. p. 49–125.
  37. Rørå AMB, et al. Influence of high content of dietary soybean oil on quality of large fresh, smoked and frozen Atlantic salmon (Salmo salar). Aquacult Int. 2005;13:217–31. · doi:10.1007/s10499-004-1074-0
  38. Torstensen BE, et al. Tailoring of Atlantic Salmon (Salmo salar L) Flesh Lipid Composition and Sensory Quality by Replacing Fish Oil with a Vegetable Oil Blend. J Agri Food Chem. 2005;53:10166–78. · DOI · Paper page
  39. Barnes PM, et al. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Rep. 2007;2008:1–23.
  40. Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;89:1–8. · DOI · Paper page
  41. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;25:46–52.
  42. Sullivan JC, et al. Modeling the primary oxidation in commercial fish oil preparations. Lipids. 2011;46:87–93. · DOI
  43. Turner R, et al. Are the health benefits of fish oils limited by products of oxidation? Nutr Res Rev. 2006;19:53–62. · DOI · Paper page
  44. Nogueira MS, et al. Effect of long-term ingestion of weakly oxidised flaxseed oil on biomarkers of oxidative stress in LDL-receptor knockout mice. Br J Nutr. 2016;116:258–69. · DOI · Paper page
  45. Albert BB, et al. Oxidation of marine omega-3 supplements and human health. Biomed Res Int. 2013;2013:1–8. · DOI · Paper page
  46. Ritter JC, et al. Quality analysis of commercial fish oil preparations. J Sci Food Agric. 2013;93:1935–9. · DOI · Paper page
  47. O’Connell TD, et al. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur Heart J Suppl. 2020;22:J3-j20. · DOI
  48. Bonafini S, Fava C. Omega-3 fatty acids and cytochrome P450-derived eicosanoids in cardiovascular diseases: Which actions and interactions modulate hemodynamics? Prostaglandins Other Lipid Mediat. 2017;128–129:34–42. · DOI
  49. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2019;176:1038–50. · DOI · Paper page
  50. Braeckman RA, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids. 2013;89:195–201. · DOI
  51. Larsson SC, et al. Dietary long-chain n−3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79:935–45. · DOI · Paper page
  52. Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol. 2017;187:1211–21. · DOI · Paper page
  53. Gabbs M, et al. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. Adv Nutr. 2015;6:513–40. · DOI · Paper page
  54. Zhang P, et al. Dietary (n-3) Polyunsaturated Fatty Acids Modulate Murine Th1/Th2 Balance toward the Th2 Pole by Suppression of Th1 Development. J Nutr. 2005;135:1745–51. · DOI
  55. Monk JM, et al. n3 PUFAs Reduce Mouse CD4+ T-Cell Ex Vivo Polarization into Th17 Cells. J Nutr. 2013;143:1501–8. · DOI
  56. Monk JM, et al. Dietary n-3 Polyunsaturated Fatty Acids (PUFA) Decrease Obesity-Associated Th17 Cell-Mediated Inflammation during Colitis. PLoS ONE. 2012;7:e49739. · DOI
  57. Oner F, et al. Resolvin E1 Regulates Th17 Function and T Cell Activation. Frontiers in Immunology. 2021;12. · DOI
  58. •• Jacobs ML, et al. EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol. Biophys J. 2021;120:2317–29. (A biophysical study showing, once again, distinct effects of EPA and DHA on cholesterol distribution and membrane elasticity.) · DOI · Paper page
  59. Soubias O, Gawrisch K. Docosahexaenoyl chains isomerize on the sub-nanosecond time scale. J Am Chem Soc. 2007;129:6678–9. · DOI
  60. Soni SP, et al. Docosahexaenoic acid enhances segregation of lipids between raft and nonraft domains: 2H-NMR Study. Biophys J. 2008;95:203–14. · DOI · Paper page
  61. Dakroub H, et al. Eicosapentaenoic acid membrane incorporation stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages. Biochimica et Biophysica Acta (BBA) - Mole Cell Biol Lipids. 2021;1866:159016. · DOI
  62. Sherratt SCR, et al. Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2021;173. · DOI
  63. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Frontiers in Aging Neuroscience. 2015;7. · DOI · Paper page
  64. Innis SM. Dietary (n-3) Fatty Acids and Brain Development. J Nutr. 2007;137:855–9. · DOI · Paper page
  65. Querques G, et al. Retina and Omega-3. J Nutri Meta. 2011;2011:748361.
  66. Mason RP, et al. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem. 2006;281:9337–45. · DOI
  67. Mason RP, et al. Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis. Free Radical Biol Med. 1997;23:419–25. · DOI
  68. Self-Medlin Y, et al. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochem Biophys Acta. 2009;1788:1398–403. · DOI · Paper page
  69. Wratten ML, et al. Structural and dynamic effects of oxidatively modified phospholipids in unsaturated lipid membranes. Biochemistry. 1992;31:10901–7. · doi:10.1021/bi00159a034
  70. Mason RP and Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochimica et Biophysica Acta. 2015;1848. · DOI
  71. • Sherratt SCR, et al. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica et Biophysica Acta - Biomembranes. 2020;1862. (An in vitro study showing unqiue antioxidant effects of EPA compared to other fatty acids in multiple models of atherosclerosis.) · DOI · Paper page
  72. Jacob R, et al. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. J Cardiovasc Pharmacol. 2013;62:160–6. · DOI
  73. Aviram M, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998;138:271–80. · DOI · Paper page
  74. Mason RP, Jacob RF. Membrane microdomains and vascular biology: emerging role in atherogenesis. Circulation. 2003;107:2270–3. · DOI
  75. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res. 2004;53:131–42. · DOI · Paper page
  76. Pennathur S, Heinecke JW. Mechanisms for Oxidative Stress in Diabetic Cardiovascular Disease. Antioxid Redox Signal. 2007;9:955–69. · DOI · Paper page
  77. Döring Y, et al. Neutrophils in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:288–95. · DOI · Paper page
  78. Warnatsch A, et al. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science. 2015;349:316–20. · DOI · Paper page
  79. Folco EJ, et al. Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1α and Cathepsin G. Arterioscler Thromb Vasc Biol. 2018;38:1901–12. · DOI · Paper page
  80. Gimbrone MA, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118:620–36. · DOI · Paper page
  81. Steinberg D, Witztum JL. Oxidized Low-Density Lipoprotein and Atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:2311–6. · DOI · Paper page
  82. Ehara S, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–60. · DOI · Paper page
  83. Walter MF, et al. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol. 2008;51:1196–202. · DOI
  84. Walter MF, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004;44:1996–2002. · DOI · Paper page
  85. Holvoet P, et al. The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort. Diabetes. 2004;53:1068–73. · DOI · Paper page
  86. Ignarro LJ, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265–9. · DOI · Paper page
  87. Rees DD, et al. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA. 1989;86:3375–8. · DOI · Paper page
  88. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43:562–71. · DOI · Paper page
  89. Pisaniello AD, et al. Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. Atherosclerosis. 2021;324:27–37. · DOI
  90. Mason RP, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018;103:1231–7. · DOI

Cited by

See all 129

Metadata

Authors
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P.
Venue
Current Atherosclerosis Reports
Published
2022-12-29
Volume
25
Issue
1
Pages
1-17
ISSN
  • 1523-3804
  • 1534-6242
Cited by
129
References
66
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. https://app.cochat.ai/papers/10.1007/s11883-022-01075-x
The paper
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P. (2023). Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-022-01075-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.